Cell therapy growing quickly and serving rare conditions

FDA has approved a diverse group of cell and tissue therapies

May 9, 2023
What is cell therapy and how is it different than gene therapy? There are just a handful of approved cell therapies so far. But many more are lined up for approvals.

What is cell therapy?

Cell therapy involves the intravenous transfer of intact or biologically modified live cells or tissues to a patient.  Cell therapy may prevent, treat, cure, diagnosis or mitigate rare cancers, diseases or injuries. It does so without altering the underlying genetic condition. The cells are cultivated or modified outside of the body before being injected into the patient. Cell therapy restores or alters certain sets of cells, or uses cells to carry a therapy throughout the body.1,2,3 Cells or tissues used in cell-based therapies may be obtained from the patient’s own cells or tissues (autologous) or from a donor (allogeneic).

CAR-T therapy, or chimeric antigen receptor T cell therapy, uses the technologies of both gene therapy and cell therapy. For Prime’s purposes, we define CAR-T as cell therapy, not gene therapy.

Cell-DNA-illustration




What is gene therapy? What’s the difference?

Gene therapy involves the transfer of genetic material, usually in a carrier or vector, and the uptake of the gene into the appropriate cells of the body. Cell therapy involves the transfer of cells with the relevant function into the patient. Some protocols use both gene therapy and cell therapy.

Cells are the basic building blocks of all living things; genes can be found deep within cells. Genes are small sections of DNA that carry genetic information and instructions for making proteins, which help build and maintain the body.1,2,3

Cell therapies on the market as of February 2023

There are seven cell therapy products FDA-approved to date. (See “What is gene therapy?” for a list of gene therapy products.)

An estimated five to 10 cell therapies have PDUFA dates in 2023.

FDA Approved CAR T-Cell Therapy One-Time Administration or One-Time Administration Tissue-Based Therapy with WAC of  > $399,000

Name Manufacturer Indication WAC

Approval Date*

Kymriah™ (tisagenlecleucel) Novartis

Pediatric ALL &

LBCL & FL

$508,250

$399,110

August 2017

Yescarta™

(axicabtagene ciloleucel)

Kite LBCL & FL $399,000 October 2017

Tecartus™

(brexucabtagene autoleucel)

Kite Mantle cell lymphoma $399,000 July 2020

Breyanzi™

(lisocabtagene maraleucel)

BMS LBCL $410,300 February 2021

Abecma™

(idecabtagene vicleucel)

BMS and bluebird bio Multiple myeloma $419,500 March 2021
Rethymic™ (allogeneic processed thymus tissue agdc) Enzyvant Congenital athymia ~$2.7 million October 2021

Carvykti™

(ciltacabtagene autoleucel)

Janssen Relapsed and refractory multiple myeloma $465,000 February 2022

* Anticipated approval dates are predictions made by Prime Therapeutics, based on industry information.

References

  1. https://www.genemedi.net/i/ex-vivo-in-vivo-in-vitro
  2. https://asgct.org/education/more-resources/gene-and-cell-therapy-faqs#:~:text=Gene%20therapy%20involves%20the%20transfer,gene%20therapy%20and%20cell%20therapy.
  3. https://www.novartis.com/about/innovative-medicines/novartis-pharmaceuticals/novartis-gene-therapies/what-cell-and-gene-therapy#:~:text=Cells%20are%20the%20basic%20building,and%20maintain%20the%20body1.

Related news

Perspectives

July 16, 2024

LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast

In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts

Perspectives

July 12, 2024

August 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market

Perspectives

July 12, 2024

High-Cost Therapy Profile: July 2024

Detailed information about Afamitresgene autoleucel Intravenous (IV)